Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials

Few prediction models have so far been developed and assessed for the prognosis of patients who undergo curative resection for colorectal cancer (CRC). We prepared a clinical dataset including 5,530 patients who participated in three major randomized controlled trials as a training dataset and 2,263...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Oncotarget 2017-11, Vol.8 (58), p.99150-99160
Hauptverfasser: Honda, Michitaka, Oba, Koji, Akiyoshi, Takashi, Maeda, Hiromichi, Kashiwabara, Kosuke, Kanda, Mitsuro, Mayanagi, Shuhei, Aoyama, Toru, Hamada, Chikuma, Sadahiro, Sotaro, Fukunaga, Yosuke, Ueno, Masashi, Sakamoto, Junichi, Saji, Shigetoyo, Yoshikawa, Takaki
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 99160
container_issue 58
container_start_page 99150
container_title Oncotarget
container_volume 8
creator Honda, Michitaka
Oba, Koji
Akiyoshi, Takashi
Maeda, Hiromichi
Kashiwabara, Kosuke
Kanda, Mitsuro
Mayanagi, Shuhei
Aoyama, Toru
Hamada, Chikuma
Sadahiro, Sotaro
Fukunaga, Yosuke
Ueno, Masashi
Sakamoto, Junichi
Saji, Shigetoyo
Yoshikawa, Takaki
description Few prediction models have so far been developed and assessed for the prognosis of patients who undergo curative resection for colorectal cancer (CRC). We prepared a clinical dataset including 5,530 patients who participated in three major randomized controlled trials as a training dataset and 2,263 consecutive patients who were treated at a cancer-specialized hospital as a validation dataset. All subjects underwent radical resection for CRC which was histologically diagnosed to be adenocarcinoma. The main outcomes that were predicted were the overall survival (OS) and disease free survival (DFS). The identification of the variables in this nomogram was based on a Cox regression analysis and the model performance was evaluated by Harrell's c-index. The calibration plot and its slope were also studied. For the external validation assessment, risk group stratification was employed. The multivariate Cox model identified variables; sex, age, pathological T and N factor, tumor location, size, lymphnode dissection, postoperative complications and adjuvant chemotherapy. The c-index was 0.72 (95% confidence interval [CI] 0.66-0.77) for the OS and 0.74 (95% CI 0.69-0.78) for the DFS. The proposed stratification in the risk groups demonstrated a significant distinction between the Kaplan-Meier curves for OS and DFS in the external validation dataset. We established a clinically reliable nomogram to predict the OS and DFS in patients with CRC using large scale and reliable independent patient data from phase III randomized controlled trials. The external validity was also confirmed on the practical dataset.
doi_str_mv 10.18632/oncotarget.21845
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5716800</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1976002365</sourcerecordid><originalsourceid>FETCH-LOGICAL-c422t-b83e6f732587031fb6e49570c194b9e6ac0fb8c1288940e3284d7fc423fe09c03</originalsourceid><addsrcrecordid>eNpVUctuHCEQRFai2LL9AblEHHMZh8c8mEukyHmtZCkX54wYptnFYugJsCvll_yVYW3HcTjQLbqrquki5C1nV1z1UnzAaLGYtIVyJbhquxNyxsd2bETXyVcv8lNymfMdq6drByXGN-RUjEKooWdn5P4zHCDgukAs1MSZHkzwsykeI0VHDV0TbiPm4i2NuOA2mYU6TNRiwAS2mECtiRYSNa7UO5nZ2_qYINfqkWYyGWZaEx9nf_DzvlbXqnBUrEqGuoQLLbsEQMPxP02uBEDXXQXSzWZDS_Im5Avy2tUAl0_xnPz8-uX2-ntz8-Pb5vrTTWNbIUozKQm9G6To1MAkd1MP7dgNzNaFTCP0xjI3KcuFUmPLQArVzoOrWOmAjZbJc_LxkXfdTwvMts6ZTNBr8otJvzUar_-vRL_TWzzobuC9YkeC908ECX_tIRe9-GwhBBMB91nzsa6eCdl3tZU_ttqEOSdwzzKc6Qeb9T-b9YPNFfPu5XzPiL-myj819qsG</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1976002365</pqid></control><display><type>article</type><title>Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free E- Journals</source><source>PubMed Central Open Access</source><creator>Honda, Michitaka ; Oba, Koji ; Akiyoshi, Takashi ; Maeda, Hiromichi ; Kashiwabara, Kosuke ; Kanda, Mitsuro ; Mayanagi, Shuhei ; Aoyama, Toru ; Hamada, Chikuma ; Sadahiro, Sotaro ; Fukunaga, Yosuke ; Ueno, Masashi ; Sakamoto, Junichi ; Saji, Shigetoyo ; Yoshikawa, Takaki</creator><creatorcontrib>Honda, Michitaka ; Oba, Koji ; Akiyoshi, Takashi ; Maeda, Hiromichi ; Kashiwabara, Kosuke ; Kanda, Mitsuro ; Mayanagi, Shuhei ; Aoyama, Toru ; Hamada, Chikuma ; Sadahiro, Sotaro ; Fukunaga, Yosuke ; Ueno, Masashi ; Sakamoto, Junichi ; Saji, Shigetoyo ; Yoshikawa, Takaki</creatorcontrib><description>Few prediction models have so far been developed and assessed for the prognosis of patients who undergo curative resection for colorectal cancer (CRC). We prepared a clinical dataset including 5,530 patients who participated in three major randomized controlled trials as a training dataset and 2,263 consecutive patients who were treated at a cancer-specialized hospital as a validation dataset. All subjects underwent radical resection for CRC which was histologically diagnosed to be adenocarcinoma. The main outcomes that were predicted were the overall survival (OS) and disease free survival (DFS). The identification of the variables in this nomogram was based on a Cox regression analysis and the model performance was evaluated by Harrell's c-index. The calibration plot and its slope were also studied. For the external validation assessment, risk group stratification was employed. The multivariate Cox model identified variables; sex, age, pathological T and N factor, tumor location, size, lymphnode dissection, postoperative complications and adjuvant chemotherapy. The c-index was 0.72 (95% confidence interval [CI] 0.66-0.77) for the OS and 0.74 (95% CI 0.69-0.78) for the DFS. The proposed stratification in the risk groups demonstrated a significant distinction between the Kaplan-Meier curves for OS and DFS in the external validation dataset. We established a clinically reliable nomogram to predict the OS and DFS in patients with CRC using large scale and reliable independent patient data from phase III randomized controlled trials. The external validity was also confirmed on the practical dataset.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.21845</identifier><identifier>PMID: 29228760</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Clinical Research Paper</subject><ispartof>Oncotarget, 2017-11, Vol.8 (58), p.99150-99160</ispartof><rights>Copyright: © 2017 Honda et al. 2017</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c422t-b83e6f732587031fb6e49570c194b9e6ac0fb8c1288940e3284d7fc423fe09c03</citedby><cites>FETCH-LOGICAL-c422t-b83e6f732587031fb6e49570c194b9e6ac0fb8c1288940e3284d7fc423fe09c03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716800/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5716800/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29228760$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Honda, Michitaka</creatorcontrib><creatorcontrib>Oba, Koji</creatorcontrib><creatorcontrib>Akiyoshi, Takashi</creatorcontrib><creatorcontrib>Maeda, Hiromichi</creatorcontrib><creatorcontrib>Kashiwabara, Kosuke</creatorcontrib><creatorcontrib>Kanda, Mitsuro</creatorcontrib><creatorcontrib>Mayanagi, Shuhei</creatorcontrib><creatorcontrib>Aoyama, Toru</creatorcontrib><creatorcontrib>Hamada, Chikuma</creatorcontrib><creatorcontrib>Sadahiro, Sotaro</creatorcontrib><creatorcontrib>Fukunaga, Yosuke</creatorcontrib><creatorcontrib>Ueno, Masashi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Saji, Shigetoyo</creatorcontrib><creatorcontrib>Yoshikawa, Takaki</creatorcontrib><title>Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>Few prediction models have so far been developed and assessed for the prognosis of patients who undergo curative resection for colorectal cancer (CRC). We prepared a clinical dataset including 5,530 patients who participated in three major randomized controlled trials as a training dataset and 2,263 consecutive patients who were treated at a cancer-specialized hospital as a validation dataset. All subjects underwent radical resection for CRC which was histologically diagnosed to be adenocarcinoma. The main outcomes that were predicted were the overall survival (OS) and disease free survival (DFS). The identification of the variables in this nomogram was based on a Cox regression analysis and the model performance was evaluated by Harrell's c-index. The calibration plot and its slope were also studied. For the external validation assessment, risk group stratification was employed. The multivariate Cox model identified variables; sex, age, pathological T and N factor, tumor location, size, lymphnode dissection, postoperative complications and adjuvant chemotherapy. The c-index was 0.72 (95% confidence interval [CI] 0.66-0.77) for the OS and 0.74 (95% CI 0.69-0.78) for the DFS. The proposed stratification in the risk groups demonstrated a significant distinction between the Kaplan-Meier curves for OS and DFS in the external validation dataset. We established a clinically reliable nomogram to predict the OS and DFS in patients with CRC using large scale and reliable independent patient data from phase III randomized controlled trials. The external validity was also confirmed on the practical dataset.</description><subject>Clinical Research Paper</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNpVUctuHCEQRFai2LL9AblEHHMZh8c8mEukyHmtZCkX54wYptnFYugJsCvll_yVYW3HcTjQLbqrquki5C1nV1z1UnzAaLGYtIVyJbhquxNyxsd2bETXyVcv8lNymfMdq6drByXGN-RUjEKooWdn5P4zHCDgukAs1MSZHkzwsykeI0VHDV0TbiPm4i2NuOA2mYU6TNRiwAS2mECtiRYSNa7UO5nZ2_qYINfqkWYyGWZaEx9nf_DzvlbXqnBUrEqGuoQLLbsEQMPxP02uBEDXXQXSzWZDS_Im5Avy2tUAl0_xnPz8-uX2-ntz8-Pb5vrTTWNbIUozKQm9G6To1MAkd1MP7dgNzNaFTCP0xjI3KcuFUmPLQArVzoOrWOmAjZbJc_LxkXfdTwvMts6ZTNBr8otJvzUar_-vRL_TWzzobuC9YkeC908ECX_tIRe9-GwhBBMB91nzsa6eCdl3tZU_ttqEOSdwzzKc6Qeb9T-b9YPNFfPu5XzPiL-myj819qsG</recordid><startdate>20171117</startdate><enddate>20171117</enddate><creator>Honda, Michitaka</creator><creator>Oba, Koji</creator><creator>Akiyoshi, Takashi</creator><creator>Maeda, Hiromichi</creator><creator>Kashiwabara, Kosuke</creator><creator>Kanda, Mitsuro</creator><creator>Mayanagi, Shuhei</creator><creator>Aoyama, Toru</creator><creator>Hamada, Chikuma</creator><creator>Sadahiro, Sotaro</creator><creator>Fukunaga, Yosuke</creator><creator>Ueno, Masashi</creator><creator>Sakamoto, Junichi</creator><creator>Saji, Shigetoyo</creator><creator>Yoshikawa, Takaki</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20171117</creationdate><title>Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials</title><author>Honda, Michitaka ; Oba, Koji ; Akiyoshi, Takashi ; Maeda, Hiromichi ; Kashiwabara, Kosuke ; Kanda, Mitsuro ; Mayanagi, Shuhei ; Aoyama, Toru ; Hamada, Chikuma ; Sadahiro, Sotaro ; Fukunaga, Yosuke ; Ueno, Masashi ; Sakamoto, Junichi ; Saji, Shigetoyo ; Yoshikawa, Takaki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c422t-b83e6f732587031fb6e49570c194b9e6ac0fb8c1288940e3284d7fc423fe09c03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Clinical Research Paper</topic><toplevel>online_resources</toplevel><creatorcontrib>Honda, Michitaka</creatorcontrib><creatorcontrib>Oba, Koji</creatorcontrib><creatorcontrib>Akiyoshi, Takashi</creatorcontrib><creatorcontrib>Maeda, Hiromichi</creatorcontrib><creatorcontrib>Kashiwabara, Kosuke</creatorcontrib><creatorcontrib>Kanda, Mitsuro</creatorcontrib><creatorcontrib>Mayanagi, Shuhei</creatorcontrib><creatorcontrib>Aoyama, Toru</creatorcontrib><creatorcontrib>Hamada, Chikuma</creatorcontrib><creatorcontrib>Sadahiro, Sotaro</creatorcontrib><creatorcontrib>Fukunaga, Yosuke</creatorcontrib><creatorcontrib>Ueno, Masashi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Saji, Shigetoyo</creatorcontrib><creatorcontrib>Yoshikawa, Takaki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Honda, Michitaka</au><au>Oba, Koji</au><au>Akiyoshi, Takashi</au><au>Maeda, Hiromichi</au><au>Kashiwabara, Kosuke</au><au>Kanda, Mitsuro</au><au>Mayanagi, Shuhei</au><au>Aoyama, Toru</au><au>Hamada, Chikuma</au><au>Sadahiro, Sotaro</au><au>Fukunaga, Yosuke</au><au>Ueno, Masashi</au><au>Sakamoto, Junichi</au><au>Saji, Shigetoyo</au><au>Yoshikawa, Takaki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2017-11-17</date><risdate>2017</risdate><volume>8</volume><issue>58</issue><spage>99150</spage><epage>99160</epage><pages>99150-99160</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>Few prediction models have so far been developed and assessed for the prognosis of patients who undergo curative resection for colorectal cancer (CRC). We prepared a clinical dataset including 5,530 patients who participated in three major randomized controlled trials as a training dataset and 2,263 consecutive patients who were treated at a cancer-specialized hospital as a validation dataset. All subjects underwent radical resection for CRC which was histologically diagnosed to be adenocarcinoma. The main outcomes that were predicted were the overall survival (OS) and disease free survival (DFS). The identification of the variables in this nomogram was based on a Cox regression analysis and the model performance was evaluated by Harrell's c-index. The calibration plot and its slope were also studied. For the external validation assessment, risk group stratification was employed. The multivariate Cox model identified variables; sex, age, pathological T and N factor, tumor location, size, lymphnode dissection, postoperative complications and adjuvant chemotherapy. The c-index was 0.72 (95% confidence interval [CI] 0.66-0.77) for the OS and 0.74 (95% CI 0.69-0.78) for the DFS. The proposed stratification in the risk groups demonstrated a significant distinction between the Kaplan-Meier curves for OS and DFS in the external validation dataset. We established a clinically reliable nomogram to predict the OS and DFS in patients with CRC using large scale and reliable independent patient data from phase III randomized controlled trials. The external validity was also confirmed on the practical dataset.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29228760</pmid><doi>10.18632/oncotarget.21845</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1949-2553
ispartof Oncotarget, 2017-11, Vol.8 (58), p.99150-99160
issn 1949-2553
1949-2553
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5716800
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free E- Journals; PubMed Central Open Access
subjects Clinical Research Paper
title Development and validation of a prognostic nomogram for colorectal cancer after radical resection based on individual patient data from three large-scale phase III trials
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T19%3A12%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20and%20validation%20of%20a%20prognostic%20nomogram%20for%20colorectal%20cancer%20after%20radical%20resection%20based%20on%20individual%20patient%20data%20from%20three%20large-scale%20phase%20III%20trials&rft.jtitle=Oncotarget&rft.au=Honda,%20Michitaka&rft.date=2017-11-17&rft.volume=8&rft.issue=58&rft.spage=99150&rft.epage=99160&rft.pages=99150-99160&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.21845&rft_dat=%3Cproquest_pubme%3E1976002365%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1976002365&rft_id=info:pmid/29228760&rfr_iscdi=true